小左心室患者连续流左心室辅助装置植入
本研究在本中心2003年11月至2016年3月间纳入511例连续流左心室辅助装置(LVAD)植入患者,比较术前小左心室(左心室舒张末期内径≤5.5 cm)与非小左心室患者的围术期特征、并发症及长期生存。HeartMate II组小左心室患者24个月生存率66.8% vs 56.1%(p=0.17),非小左心室患者总生存显著更优(p=0.02);HVAD组分别为71.3% vs 70.8%(p=0.96),总生存无显著差异(p=0.89)。作者认为选择装置时可考虑HVAD在小左心室患者中的生存优势。
要点
- 术前小左心室定义为左心室舒张末期内径≤5.5 cm。
- HeartMate II组小左心室患者总生存显著劣于非小左心室患者(p=0.02)。
- HVAD组小左心室与非小左心室患者总生存无显著差异(p=0.89)。
核心结论
- 尽管两种装置的植入指征不同,本研究提示为小左心室患者选择装置时应考虑HVAD植入相关的生存优势。
研究设计与样本
- 本中心2003年11月至2016年3月间511例初次植入HeartMate II(n=393)或HeartWare HVAD(n=118)的患者队列。
- 术前小左心室定义为左心室舒张末期内径≤5.5 cm。
- 比较小左心室与非小左心室患者的围术期特征、并发症和长期生存。
主要发现
- HeartMate II组:非小左心室352例,小左心室41例;24个月生存率非小左心室66.8% vs 小左心室56.1%(p=0.17);非小左心室患者总生存显著更优(p=0.02)。
- HVAD组:非小左心室94例,小左心室24例;24个月生存率非小左心室71.3% vs 小左心室70.8%(p=0.96);总生存无显著差异(p=0.89)。
关键数值与推荐
- 术前小左心室定义为左心室舒张末期内径≤5.5 cm。
- HeartMate II组24个月生存率:非小左心室66.8% vs 小左心室56.1%(p=0.17)。
- HVAD组24个月生存率:非小左心室71.3% vs 小左心室70.8%(p=0.96)。
临床怎么用
- 作者认为,为小左心室患者选择装置时,应考虑HVAD植入相关的生存优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Having a preoperative small left ventricle (LV) has been associated with higher complication and mortality rates after left ventricular assist device (LVAD) implantation; however, the outcomes after continuous-flow LVAD implantation have not been well studied. This is the first large-scale analysis of long-term survival after continuous-flow LVAD implantation in patients with a preoperative small LV. METHODS: Our cohort comprised 511 patients who underwent primary implantation of a HeartMate II (n = 393 [Thoratec, Pleasanton, CA]) or HeartWare HVAD (n = 118 [HeartWare International, Framingham, MA]) at our institution between November 2003 and March 2016. Preoperative small LV was defined as having an LV end-diastolic diameter of 5.5 cm or less. HeartMate II and HVAD recipients with a small LV were compared with patients not having a small LV in terms of perioperative characteristics, complications, and long-term survival. RESULTS: The HeartMate II was implanted in 393 patients (non-small LV, n = 352; small LV, n = 41), and the HVAD was implanted in 118 patients (non-small LV, n = 94; small LV, n = 24). For the HeartMate II recipients, the 24-month survival rate was 66.8% for the non-small LV patients and 56.1% for the small LV patients (p = 0.17); non-small LV patients had significantly better overall survival (p = 0.02). For the HVAD recipients, the 24-month survival rate was 71.3% for the non-small LV patients and 70.8% for the small LV patients (p = 0.96); these groups showed no significant difference in overall survival (p = 0.89). CONCLUSIONS: Although the indications for implantation are different for these two devices, our study suggests that the survival advantage associated with HVAD implantation should be considered when selecting a device for small LV patients.
引用
- Kawabori M, Kurihara C, Sugiura T, et al. Continuous-Flow Left Ventricular Assist Device Implantation in Patients With a Small Left Ventricle. Ann Thorac Surg. 2017. PMID: 29290308. doi:10.1016/j.athoracsur.2017.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。